Stopping Onabotulinum Treatment after the First Two Cycles Might Not Be Justified: Results of a Real-life Monocentric Prospective Study in Chronic Migraine

INTRODUCTION: Onabotulinum toxin A (OnabotA) cyclic treatment is approved for the prophylactic treatment of chronic migraine (CM), a highly disabling disorder. Although treatment response varies among patients, current guidelines suggest to stop treatment after cycle 2 if no response is achieved. Th...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Front Neurol
Autori principali: Sarchielli, Paola, Romoli, Michele, Corbelli, Ilenia, Bernetti, Laura, Verzina, Angela, Brahimi, Elona, Eusebi, Paolo, Caproni, Stefano, Calabresi, Paolo
Natura: Artigo
Lingua:Inglês
Pubblicazione: Frontiers Media S.A. 2017
Soggetti:
Neuroscience
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5723003/
https://ncbi.nlm.nih.gov/pubmed/29255444
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fneur.2017.00655
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi